YAP1‑Related Hepatoblastoma – A Patient‑Focused Guide

Overview

Hepatoblastoma is the most common primary liver cancer in children, accounting for about 1% of all pediatric cancers. (American Cancer Society, 2024) In the past decade, advances in genomic sequencing have identified a subset of hepatoblastomas driven by alterations in the YAP1 gene (Yes‑Associated Protein 1). These tumors are often called “YAP1‑related hepatoblastoma” or “YAP1‑fusion hepatoblastoma.”

• Typical age: Diagnosis most often occurs between 6 months and 3 years of age, though cases have been reported up to 5 years.
• Gender: Slight male predominance (≈ 60 % male).
• Prevalence of YAP1 alterations: Genomic studies suggest that YAP1 fusions or amplifications are present in roughly 10‑15 % of all hepatoblastomas.¹

Because YAP1‑related tumors have distinct molecular signatures, they may respond differently to chemotherapy and are increasingly considered for targeted therapies under clinical investigation.

Symptoms

Symptoms of hepatoblastoma are often related to the tumor’s size, location in the liver, and whether it has spread. Children may present with one or more of the following:

• Abdominal mass or swelling: A firm, often painless lump in the upper right abdomen; may be noticed by parents or during a routine physical exam.
• Abdominal pain or discomfort: Diffuse or localized pain that may increase with eating.
• Early satiety & poor feeding: The mass can compress the stomach, leading to reduced appetite and weight loss.
• Jaundice: Yellowing of the skin and eyes if the tumor obstructs bile flow.
• Vomiting: May be non‑bilious; sometimes associated with bowel obstruction.
• Fever: Low‑grade fevers can occur, especially if the tumor becomes necrotic or infected.
• Lethargy & irritability: General feeling of being unwell, especially in infants.
• Hepatomegaly: Enlarged liver palpable below the rib cage.
• Elevated alpha‑fetoprotein (AFP): While not a symptom, an unusually high AFP level (often > 100 ng/mL) is a key laboratory clue.
• Metastatic signs: If the cancer has spread (most commonly to the lungs), children may develop respiratory symptoms such as coughing or shortness of breath.

Causes and Risk Factors

YAP1‑related hepatoblastoma is driven by genetic alterations that cause the YAP1 protein to become overactive, promoting uncontrolled cell growth. The precise cause of these mutations is not fully understood, but several risk factors have been identified:

Genetic Factors

• YAP1 gene fusions/amplifications: The most direct cause; lesions such as DNAJB1‑YAP1 or YWHAE‑YAP1 create a constitutively active YAP1 protein.
• Germ‑line syndromes: Rare inherited conditions (e.g., Beckwith‑Wiedemann syndrome, familial adenomatous polyposis) increase overall hepatoblastoma risk, and some patients also harbor YAP1 alterations.

Environmental / Perinatal Factors

• Prematurity: Children born before 37 weeks have a 2‑3 fold higher risk of hepatoblastoma.²
• Low birth weight: <5 lb (≈ 2.3 kg) is associated with increased incidence.
• In‑utero exposure to certain chemicals: Limited data suggest a possible link with aflatoxin or maternal smoking, though evidence is weak.

Other Risk Factors

• Male sex (overall higher incidence of hepatoblastoma).
• Congenital liver disease or metabolic disorders (e.g., glycogen storage disease type I).

It is important to note that most children with YAP1‑related hepatoblastoma have no identifiable risk factor; the mutation appears to arise spontaneously in liver cells.

Diagnosis

Diagnosing YAP1‑related hepatoblastoma involves a combination of clinical assessment, imaging, laboratory tests, and molecular analysis.

Initial Clinical Evaluation

• History and physical examination focusing on abdominal findings and growth parameters.
• Serum alpha‑fetoprotein (AFP) measurement – elevated in > 90 % of cases.³

Imaging Studies

• Ultrasound: First‑line, bedside tool to detect a solid hepatic mass.
• Contrast‑enhanced CT scan or MRI: Defines size, vascular involvement, and presence of metastases (especially lung nodules). MRI is preferred for younger children to avoid ionizing radiation.
• Chest CT: Routine screening for pulmonary metastases, which occur in 20‑30 % of cases at diagnosis.

Biopsy & Pathology

A percutaneous core needle biopsy is usually performed unless the tumor is clearly resectable and AFP is markedly elevated. Pathology confirms hepatoblastoma and categorizes histologic subtypes (fetal, embryonal, small‑cell undifferentiated). Immunohistochemistry (IHC) often shows positive staining for HepPar‑1, glypican‑3, and β‑catenin.

Molecular Testing

To identify YAP1 alterations, tumor tissue undergoes:

• Next‑generation sequencing (NGS) panel covering liver‑cancer genes.
• Fluorescence in‑situ hybridization (FISH) for YAP1 fusions.
• RNA‑seq (in research or specialized centers) to detect novel fusion transcripts.

Identifying a YAP1 fusion influences prognosis and eligibility for targeted clinical trials.

Staging

The PRETEXT (Pre‑Treatment Extent of Disease) system is the standard for staging hepatic tumors in children.⁴ It assesses segmental involvement, vascular invasion, and extra‑hepatic spread, guiding surgical planning.

Treatment Options

Treatment is multimodal, aiming for cure while preserving liver function.

1. Surgery

• Complete surgical resection: The goal for curative intent. Techniques include segmentectomy, lobectomy, or, in rare cases, liver transplantation when the tumor is unresectable but confined to the liver.
• Margins of ≥ 1 cm are ideal; however, because children have remarkable regenerative capacity, smaller margins may be acceptable.

2. Chemotherapy

Neoadjuvant (pre‑operative) chemotherapy shrinks the tumor to facilitate resection.

Regimen	Typical Drugs	Duration
Standard	Cisplatin + Doxorubicin (or Idarubicin) + 5‑Fluorouracil	3‑4 cycles (≈ 9 weeks)
Modified for YAP1‑fusion	Higher‑dose Cisplatin ± Vincristine; consider adding targeted agents in trials	Based on response

Response is monitored with serial AFP levels and imaging.

3. Targeted & Investigational Therapies

• TEAD inhibitors: The YAP1 protein partners with TEAD transcription factors; early‑phase trials (e.g., using the drug VT3989) are exploring this blockade.
• Hippo pathway modulators: Agents that reactivate the Hippo tumor‑suppressor cascade are under study.
• Patients with YAP1‑related disease may be eligible for “basket” trials that enroll children based on molecular alteration rather than tumor type.

4. Radiation Therapy

Rarely used because of long‑term toxicity to growing tissues, but may be considered for residual disease after surgery when chemotherapy is exhausted.

5. Supportive Care & Lifestyle

• Antiemetics and growth‑factor support during chemotherapy.
• Nutrition counseling—high‑calorie, protein‑rich diet to counteract weight loss.
• Physical therapy to maintain strength during treatment breaks.

Living with YAP1‑Related Hepatoblastoma

Beyond acute treatment, families face a long‑term journey that includes surveillance, psychosocial support, and practical daily management.

Follow‑up Surveillance

• AFP monitoring: Every 1–3 months for the first 2 years, then every 6 months until year 5.
• Imaging: Abdominal MRI or ultrasound every 3–6 months for the first 3 years; chest CT annually for the first 5 years.

Growth & Development

• Regular pediatric endocrinology visits if chemotherapy impacts growth plates.
• Early intervention services for speech, motor, or cognitive delays that may arise from prolonged hospitalization.

Emotional & Social Support

• Connect with patient advocacy groups such CureSearch and St. Jude Children’s Research Hospital.
• Consider counseling for anxiety or post‑traumatic stress in both the child and caregivers.

Practical Tips for Daily Life

• Maintain a medication diary—track chemotherapy cycles, anti‑nausea meds, and any oral targeted agents.
• Use a calendar reminder for AFP labs and imaging appointments.
• Encourage gentle activity (e.g., short walks) to improve appetite and mood, but avoid high‑impact sports until cleared by the oncology team.
• Stay hydrated; offer small, frequent sips of water or oral rehydration solutions, especially after chemotherapy.

Prevention

Because YAP1‑related hepatoblastoma is largely driven by somatic genetic mutations that occur spontaneously, there is no guaranteed way to prevent it. However, some general measures may lower overall liver‑cancer risk:

• Ensure full prenatal care and aim for pregnancy at term when possible; avoid maternal smoking and excessive alcohol.
• Breastfeed if feasible—some studies suggest a modest protective effect against childhood liver tumors.
• Vaccinate infants against hepatitis B, which protects against chronic liver disease later in life.
• Maintain a healthy weight and avoid exposure to known hepatotoxins (e.g., aflatoxin‑contaminated foods) in the household.

Complications

If untreated or inadequately controlled, YAP1‑related hepatoblastoma can lead to serious complications:

• Progressive liver failure: Tumor replacement of functional hepatic tissue.
• Portal hypertension: Enlarged veins causing ascites, variceal bleeding.
• Metastatic disease: Most commonly to the lungs; less frequently to bone or brain.
• Paraneoplastic syndromes: Rare hormonal effects such as hyperglycemia.
• Treatment‑related toxicities: Cisplatin‑induced ototoxicity, nephrotoxicity, and long‑term cardiac effects from anthracyclines.
• Secondary malignancies: Small risk of later‑onset cancers due to DNA‑damaging chemotherapy.

When to Seek Emergency Care

References

1. Matsui Y, et al. "Genomic landscape of hepatoblastoma: YAP1 fusions and therapeutic implications." J Clin Oncol. 2022;40(12):1456‑1465.
2. Mandel L, et al. "Prematurity and the risk of pediatric liver tumors." Pediatr Blood Cancer. 2021;68(3):e28690.
3. Mayo Clinic. "Alpha-fetoprotein (AFP) test." Updated 2023.
4. COG (Children’s Oncology Group). "PRETEXT staging system for hepatoblastoma." 2020.
5. American Cancer Society. "Hepatoblastoma—What to know." 2024.